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Marketing Authorization Applications Made 
to the European Medicines Agency in 
2018– 2019: What was the Contribution of 
Real- World Evidence?
Robert Flynn1,2,†, Kelly Plueschke1,†, Chantal Quinten1, Valerie Strassmann3, Ruben G. Duijnhoven1,4, 
Maria Gordillo- Marañon1,5, Marcia Rueckbeil1,6, Catherine Cohet1 and Xavier Kurz1,*
Information derived from routinely collected real- world data has for a long time been used to support regulatory 
decision making on the safety of drugs and has more recently been used to support marketing authorization 
submissions to regulators. There is a lack of detailed information on the use and types of this real- world evidence 
(RWE) as submitted to regulators. We used resources held by the European Medicines Agency (EMA) to describe the 
characteristics of RWE included in new marketing authorization applications (MAAs) and extensions of indication 
(EOIs) for already authorized products submitted to the EMA in 2018 and 2019. For MAAs, 63 of 158 products 
(39.9%) contained RWE with a total of 117 studies. For 31.7% of these products, the RWE submitted was derived 
from data collected before the planned authorization. The most common data sources were registries (60.3%) 
followed by hospital data (31.7%). RWE was mainly included to support safety (87.3%) and efficacy (49.2%) with 
cohort studies being the most frequently used study design (88.9%). For EOIs, 28 of 153 products (18.3%) contained 
RWE with a total of 36 studies. For 57.1% of these products, studies were conducted prior to the EOIs. RWE sources 
were mainly registries (35.6%) and hospital data (27.0%). RWE was typically used to support safety (82.1%) and 
efficacy (53.6%). Cohort studies were the most commonly used study design (87.6%). We conclude that there is 
widespread use of RWE to support evaluation of MAAs and EOIs submitted to the EMA and identify areas where 
further research is required.
“Real- world evidence” (RWE) has been defined as the information 
derived from analysis of routinely collected real- world data (RWD) 
relating to a patient’s health status or the delivery of health care 
from a variety of sources other than traditional clinical trials.1 The 
use of RWE to support regulatory decision making is not new. For 
decades, such data have been used in the postauthorization phase 
for safety signal evaluation, risk management, and for studies to 
support life cycle benefit- risk evaluation. A review of postmarket-
ing assessments conducted by the European Medicines Agency 
(EMA) in 2019, showed that noninterventional studies commonly 
contributed to the evaluation of referrals related to both products’ 
safety and efficacy.2 Although randomized clinical trials (RCTs) 
represent the gold standard for studying drug efficacy because they 
prevent systematic bias in allocation of treatment,3 they cannot 
answer certain questions, for example, effectiveness under normal 
conditions of use, and may not be practical in some circumstances, 
for example, in very rare diseases or populations. The rapid pace 
of change in the scientific and technological landscapes is shift-
ing the regulatory landscape. An increasing number of medicines, 
such as advanced therapy medicinal products (ATMPs) and or-
phan products for conditions with significant unmet need, face 
challenges when aligning with the traditional drug development 
pathway, where traditional RCTs may be unfeasible, unethical, or 
less well suited to “precision medicines” that increasingly require 
analysis on subsets of patients on complex treatment pathways.1,4,5
Whereas methodological challenges remain before RWE can 
become a routine part of decision making across all parts of drug 
development,6 RWE can still have a substantial impact on regu-
latory decision making, for example, by informing on the natural 
history of disease and standards of care, by contextualizing results 
of uncontrolled trials when used as comparator groups of patients 
for single arm trials, or by collecting follow- up data to generate 
postauthorization evidence on long- term safety and effectiveness 
of medicinal products.1
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Currently, there is a lack of detailed information on the use 
of RWE in marketing authorization applications in terms of ob-
jectives (for example, to assess safety or efficacy endpoints, use 
in special populations, or inform risk management planning), 
data sources, methods, the strengths and weaknesses of these, 
and the outcome of its assessment. Previously published studies 
on the topic have been dependent on information available in 
the public domain, for example, European Public Assessment 
Reports (EPARs), and have therefore based their evaluation on 
products that complete the authorization process rather than 
those submitted for authorization,2,4,7 thereby ignoring evi-
dence submitted in withdrawn applications. In addition, con-
sidering exclusively the evidence leading to a final opinion by 
the EMA Committee for Medicinal Products for Human Use 
(CHMP) provides only a partial picture of the usefulness of 
RWE for marketing authorization. An evaluation of the total-
ity of the information, including the nonpublished assessment 
of products that were withdrawn or for which additional data 
were requested during the assessment procedure, would support 
the provision of recommendations for best practice, improve 
the efficient use of RWE for regulatory applications, and en-
able assessment of the needs for data validation, expertise, and 
training. As recently pointed out, clarity is needed around ter-
minology and practice when considering interventional or non-
interventional designs, primary collection or secondary use of 
data, and characteristics of comparison group(s), as well as an 
assessment of prognostic determinism for the corresponding 
cause- effect association.8
This article describes the first phase of a project aiming to evalu-
ate the impact of RWE in the decision- making process of medicinal 
products. The ultimate objective is to develop guidance targeted at 
various stakeholders to promote use of high quality RWD in reg-
ulatory decision making.9 It provides a description of the charac-
teristics and subsequent approval status of RWE included in new 
marketing authorization applications (MAAs) and extensions of 
indication (EOIs) for previously authorized products submitted to 
the EMA in 2018 and 2019.
METHODS
Definitions
RWD were defined as routinely collected patient- level data relating to 
their health status and/or the delivery of health care from a variety of 
sources other than RCTs. RWE was then defined as the information de-
rived from RWD.1 For the purpose of this study, these conceptual defi-
nitions were translated into operational criteria, as illustrated in Table 1. 
In the context of clinical trials, the definition includes the use of observa-
tional data to support and complement RCTs, even types of clinical trial 
considered interventional.
Products of interest
All applications for MAAs and EOIs submitted from January 1, 2018, 
to December 31, 2019, and assessed by the CHMP were included. This 
study period was used as it was anticipated that CHMP assessment 
reports (ARs) would have been finalized by the time of the study lock 
point for data extraction of August 12, 2020. Applications for generic 
medicines (medicines developed to be the same as an already authorized 
reference medicine), informed consent applications (referring to the 
pharmaceutical, preclinical, and clinical data of a reference product), and 
well- established use applications (based on results from the scientific lit-
erature when the active ingredient has been used for more than 10 years 
and its efficacy and safety have been well- established) were excluded to 
avoid either a double- counting of the same information or use of infor-
mation submitted outside the study period.
Data extraction and analysis
New MAAs and EOIs were identified from the EMA’s product infor-
mation and application tracking system (SIAMED)10 and exported 
into an Excel file with administrative information: this list was inclu-
sive of the European Commission Register of medicinal products (the 
Community Register) of marketing authorization of the products in 
the European Union,11 and so was considered a complete list of eligi-
ble products. Information on pediatric use, ATMP status, and PRIME 
status (“priority medicines” status that enhances EMA’s support for the 
development of medicines that target an unmet medical need) were col-
lected from internal data sources.12,13 The presence of RWD or RWE in 
the application was primarily identified from the CHMP AR retrieved 
from electronic archives held at the EMA. The AR and the version of the 
Risk Management Plan (RMP) most closely linked to the authorization 
of the product were manually searched for a series of characteristics of 
RWD/RWE. For MAAs and EOIs withdrawn during the application 
Table 1 Types of real- world data / real- world evidence included/excluded in new MAAs and EOIs for already authorized 
products
Included as RWD/RWE Not included as RWD/RWE
• Patient- based non- interventional pre- or postauthorizsation studies per-
formed to support the marketing authorization application (primary and/or 
secondary use of data)
• Use of RWD source(s) (e.g., registry, electronic health care records, medical 
charts, etc.) to provide comparator (historical or contemporaneous) arms in 
single arm trials
• Use of RWD source(s) in the context of RCTs (e.g., to assess the representa-
tiveness of the control arm)
• Use of RWD data source(s) to support the implementation of clinical tri-
als (e.g., by facilitating identification of eligible patients or type of data 
collection)
• Product- related literature review (e.g., on real- world safety data of the prod-
uct in other indications)
• Non- product related literature review (for example 
reviews related to the natural history of the targeted 
disease or comorbidities associated with the disease)
• Use of aggregated epidemiological data from multiple 
sources where attribution is unclear
• Interventional studies (phase I, II), including preclinical 
studies, toxicological studies, dose- response studies, 
drug- drug interaction studies
• Phase III/IV studies without RWD/RWE use (e.g., 
single- arm study without comparator group from RWD)
• Open- label follow- up studies of clinical trial patients
• Routine pharmacovigilance activities
• Active surveillance based on spontaneous reporting
• Surveys not based on individual patients (e.g., surveys 
of physicians to assess awareness of risk minimization 
measures)
EOIs, extensions of indications; MAAs, authorization applications; RCT, randomized clinical trial; RWD, real- world data; RWE, real- world evidence.
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procedure, the last AR available was searched. Where the information 
available in the AR or RMP was unclear or did not contain enough de-
tails, additional files submitted by an applicant as part of the dossier were 
consulted. MAAs and EOIs were assigned randomly to seven reviewers 
who performed the screening and extraction of the required data by com-
pleting an online survey based on a predefined list of variables and ques-
tions that were to be abstracted from the available product information. 
Two electronic files— one for the initial MAAs and one for the EOIs— 
were compiled and made available for statistical analysis. The analysis of 
RWD/RWE consisted of a descriptive analysis of the information col-
lected, the number and percentages of MAAs/EOIs for which RWD/
RWE was submitted, and the distribution of RWD/RWE submission 
by: Anatomical Therapeutic Chemical (ATC) classification; whether 
pre- or postauthorization; whether included as a main or supportive 
study (“main” referring to studies identified as those pivotal to the assess-
ment process, typically identified in a specific section of the assessment 
report)14; RMP category14; the objective studied (safety, efficacy, disease 
epidemiology, drug utilization, abuse of drug, and other), data sources 
used (electronic health records, claims data, registries as identified in the 
AR, data from compassionate use program, spontaneous report database, 
reuse of data from observational studies, linked data sources, and other), 
and study design (cohort, case- control, cross- sectional, ecological, case- 
only design, and other).
Quality control
The strategy for identifying and categorizing the information was piloted 
with seven investigators independently extracting and discussing the data 
for an initial three MAAs to ensure common understanding of how to 
meet the study’s objectives and to agree on the criteria for the categories 
of information to be included and excluded. During the actual review 
stage, regular meetings were organized among the reviewers to discuss 
data where an investigator was uncertain about their status as RWD/
RWE and to agree on an outcome by consensus. Two additional investi-
gators acting as quality controllers were appointed to cross- check a ran-
dom sample of 33 MAAs and 37 EOIs (error margin of 10%; confidence 
level of 80%) with stratification at reviewer level. In case of disagreement, 
the reviewer provided written comments explaining their decision and 
initiated a discussion with the investigator to reach consensus.
RESULTS
From January 1, 2018, to December 31, 2019, the EMA received 
201 MAAs and 163 EOIs applications, of which 158 and 153, 
respectively, were within the scope of the study after excluding 
applications relating to generic products (n = 38), informed con-
sent (n  =  14), and well- established use applications (n  =  1). Of 
the remaining eligible products, 63 MAAs (39.9%) and 28 EOIs 
(18.3%) contained references to RWD/RWE. The distribution by 
the ATC classification system is shown in Table 2.
At the time of data extraction from SIAMED on August 12, 
2020, 73 MAAs had been authorized (37 with RWE), 26 had 
been withdrawn or refused (4 with RWE), and 59 were still under 
evaluation by the EMA (20 with RWE). Forty- eight had a pediat-
ric indication (22 with RWE), 2 had PRIME status (neither with 
RWE) and 5 were ATMPs (3 with RWE). For EOIs applications, 
104 had been authorized (19 with RWE), 8 had been withdrawn or 
refused (1 with RWE), and 41 were still under evaluation (8 with 
RWE). Fifty- eight had a pediatric indication (15 with RWE), 6 had 
PRIME status (4 with RWE) and none were considered ATMPs.
Characteristics of the RWE that were used in support of initial 
MAAs and EOIs are shown in Table 3. The 63 MAAs included a 
total of 117 studies across products. RWD was submitted within 
the application as evidence from the pre- authorization phase for 
approximately one third of the products and had an exclusively 
supportive role in the benefit- risk assessment in 75.0% of cases. 
Applications including RWE during the postauthorization phase 
consisted mainly of RWE- based category 3 (required) studies of 
the RMP (74.1%). RWD sources were most commonly registries 
(60.3%), followed by hospital data (31.7%), and were mainly in-
cluded to support safety (87.3%) and efficacy (49.2%) objectives. 
The most frequently used registries were disease registries (33.3%) 
and product registries (those where the registry used was focused 
on patients receiving the specific medicinal product of interest; 
Table 2 Use of RWD and RWE by ATC classification
ATC classification
Initial MAAs   
n with RWE / total assessed (%)
EOIs   
n with RWE / total assessed (%)
A Alimentary tract and metabolism 6/13 (46.2) 3/14 (21.4)
B Blood and blood forming organs 7/11 (63.6) 7/10 (70.0)
C Cardiovascular system 0/4 (0) 0/3 (0)
D Dermatologicals 0/1 (0) 0/3 (0)
G Genito urinary system and sex hormones 0/0 (0) 0/0 (0)
H Systemic hormonal preparations, excl. sex hor-
mones, and insulins
1/8 (12.5) 0/0 (0)
J Anti- infectives for systemic use 14/25 (56.0) 1/19 (5.3)
L Antineoplastic and immunomodulating agents 23/61 (37.7) 12/78 (15.4)
M Musculo- skeletal system 1/1 (100) 2/2 (100)
N Nervous system 8/17 (47.1) 1/5 (20.0)
P Antiparasitic products, insecticides and repellents 0/0 (0) 0/0 (0)
R Respiratory system 1/8 (12.5) 1/14 (7.1)
S Sensory organs 2/6 (33.3) 0/2 (0)
V Various 0/3 (0) 1/3 (33.3)
ATC, Anatomical Therapeutic Chemical; EOIs, extension of indication; MAAs, marketing authorization application; RWD, real- world data; RWE, real- world evidence.
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14.3%). Cohort studies were the most frequently used observa-
tional design (88.9% of products).
The 28 EOIs products included a total of 36 studies in their 
applications. These studies were mainly conducted prior to the 
EOIs (57.1%) and were supportive (75.0%) rather than main 
studies. Applications foreseeing use of RWE during the post-
authorization phase consisted mainly of RMP category 3 stud-
ies (93.3%). RWD sources were mainly registries (46.4%) and 
hospital data (27.0%), and were typically used to support safety 
(82.1%) and efficacy (53.6%) objectives. The most frequently 
used registries were disease registries (32.1%) and products regis-
tries (10.7%). Cohort studies were the most frequently used de-
sign (87.6% of products).
We analyzed whether the objectives of the RWE generation 
differed according to whether the studies were submitted pre- 
authorization or were proposed as part of the postauthorization 
phase. Of 36 MAAs and EOIs supported with pre- authorization 
RWE, 27 (75.0%) were directed at safety and 27 (75.0%) were 
directed as efficacy/effectiveness. Of 69 MAAs and EOIs with 
Table 3 Characteristics of RWD/RWE found in initial MAAs 
and EOIs
Characteristics of RWD/RWE 
studies used
Initial MAAs  
n (%)  
Total MAAs = 63
EOIs  
n (%)  
Total EOIs = 28
Number of RWE studies 
included in applications
Total 117 36
Number of RWE studies per 
application
1 29/63 (46.0) 23/28 (75.0)
2 22/63 (34.9) 3/28 (10.7)
≥ 3 12/63 (19.1) 2/28 (14.3)
Time of implementation of 
RWE studies in applications
Pre- authorization 9/63 (14.3) 13/28 (46.4)
Postauthorization 43/63 (68.3) 12/28 (42.8)
Pre- authorization and 
postauthorization
11/63 (17.4) 3/28 (10.7)
Whether RWE studies to 
support pre- authorization 
were included as main or 
supportive studies or a 
combination of both main 
and supportive
Main study(ies) 3/20 (15.0) 4/16 (25.0)
Supportive study(ies) 15/20 (75.0) 12/16 (75.0)
Both main and supportive 
stud(ies)
2/20 (10.0) 0/16 (0.0)
EU RMP category for at 
least one postauthorization 
study, if requested
Category 1 (imposed as 
condition of MA)
11/54 (20.3) 1/15 (6.6)
Category 2 (specific obli-
gation of MA)
3/54 (5.6) 0/15 (0.0)
Category 3 (required) 40/54 (74.1) 14/15 (93.3)
Objective of RWE studies
Safety 55/63 (87.3) 23/28 (82.1)
Efficacy 31/63 (49.2) 15/28 (53.6)
Disease epidemiology 5/63 (7.9) 3/28 (10.7)
Drug utilization 13/63 (20.6) 6/28 (21.4)
Abuse of drug 6/63 (9.5) 0/28 (0.0)
Other objectives 8/63 (12.6) 3/28 (10.7)
Data sources
Electronic health care 
records from primary care
8/63 (12.7) 2/28 (7.1)
Electronic health care 
records from secondary 
care
8/63 (12.7) 0/28 (0.0)
Medical records from 
primary carea
8/63 (12.7) 5/28 (17.9)
Hospital data 20/63 (31.7) 7/28 (27.0)
Claims data 5/63 (7.9) 2/28 (7.1)
 (Continued)
Characteristics of RWD/RWE 
studies used
Initial MAAs  
n (%)  
Total MAAs = 63
EOIs  
n (%)  
Total EOIs = 28
Prescription data 6/63 (9.5) 3/28 (10.7)
Dispensing data 5/63 (7.9) 1/28 (3.6)
All registriesb 38/63 (60.3) 13/28 (46.4)
Disease registry 21/63 (33.3) 9/28 (32.1)
Product registry 9/63 (14.3) 3/28 (10.7)
Other registriesc 13/63 (20.6) 2/28 (7.1)
Data from compassionate 
use program
2/63 (3.2) 1/28 (3.5)
Spontaneous reportsd 4/63 (6.3) 3/28 (10.7)
Re- use of data from ob-
servational studies
4/63 (6.3) 1/28 (3.6)
Linked data sources 3/63 (4.7) 1/28 (3.6)
Other data sourcese 18/63 (28.6) 5/28 (17.9)
Design of noninterventional 
studies, if used as RWE
Cohort studies 56/63 (88.9) 22/28 (87.6)
Case- control 2/63 (3.1) 0/28 (0.0)
Cross- sectional 3/63 (4.7) 2/28 (7.1)
Otherf 8/63 (12.6) 3/28 (10.7)
EOIs, extensions of indication; EU RMP, European Union Risk Management 
Plan; MA, marketing authorization; MAAs, marketing authorization 
applications; RWD, real- world data; RWE, real- world evidence.
aPrimary care medical records were not always identified as electronic or 
paper based. bProducts might be associated with registries of multiple 
different types. cOther registries: pregnancy registry, birth defect registry, 
population registries, and other patient registries (unspecified). dUse of 
spontaneous reports for purposes other than routine pharmacovigilance: 
typically, these were included as part of wider safety databases incorporating 
data from multiple sources. eExample of other data sources: medical charts 
or combination of different data sources. fExample of other study types: 
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postauthorization RWE, 65 (94.2%) were directed at safety and 30 
(43.5%) were directed as efficacy/effectiveness.
The purpose for which the RWE was collected varied but in-
cluded: external/historical comparators, identification of patients 
for noninterventional studies, data collection on safety endpoints, 
data collection on efficacy, data collection on disease epidemiol-
ogy, measuring effectiveness of risk minimization measures, com-
parison of surrogate and clinical endpoints, studying patterns of 
drug utilization, and feasibility analyses. Where stated, the most 
common setting of the RWE studies was the European Union (in-
cluding the United Kingdom), followed by the United States and 
the rest of the world.
Thirty- eight MAAs and 13 EOIs made used of one or more 
registries a part of their application (Table 3, Figure 1). For ini-
tial marketing authorization applications, these were more fre-
quently postauthorization studies (30 postauthorization and 11 
pre- authorization), whereas for the EOIs applications, these were 
more balanced (7 pre- authorization and 9 postauthorization). 
We found that registry studies were imposed either as category 1 
(imposed as condition to the terms of marketing authorization) 
or category 2 (specific obligation to the terms of marketing autho-
rization) in the EU RMP, in 14 of 158 MAAs (8.9%) and 1 of 153 
EOIs (0.7%), with 4 coming from product registries and 5 from 
disease registries.
Quality control
Of the 33 MAAs and 37 EOIs cross- checked, 15 and 7 applica-
tions, respectively, resulted in disagreement. The nature of the 
disagreement related only to the detail of the data collected, for 
example, relating to pediatric indication status, the type and or-
igin of RWD sources, and uncertainty around the study design 
in the documentation. For some investigators, the discrepancies 
between reviewer and investigator, and the discussion to resolve 
them required the investigator to repeat the data extraction.
Figure 1 Pie charts showing the distribution of registry types amongst initial Marketing Authorization Applications (n = 38) and Extensions of 
Indication (n = 13).
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DISCUSSION
This study examined when and how RWE was used to support 
MAA for new products and EOIs for products currently mar-
keted. We found that RWE was used in 39.9% of MAAs (mainly 
in the postauthorization setting) and 18.3% of EOIs (balanced 
between pre- and postauthorization) submitted to the EMA. It 
is perhaps surprising that RWE was less used in support of EOIs 
applications considering RWE would already have been generated 
in the postmarketing setting. It could be that the RWE submitted 
for EOIs applications was of greater importance in the decision- 
making process, whereas perhaps being more descriptive/support-
ive for MAAs— we found that 15% of MAAs and 25% of EOIs 
had RWE present as a main study. Alternatively, for EOIs, it could 
be that concerns around safety are already addressed by ongoing 
pharmacovigilance activities following the initial marketing au-
thorization, so there is less of a role for additional RWE, which 
historically has principally been used for establishing safety. Such 
considerations will be the topic of further research.
When used pre- authorization, supportive studies commonly 
evaluated efficacy and effectiveness, whereas postauthorization 
studies were mainly RMP category 3 (for studies included in 
RMPs) focused on safety. The main RWD sources used for both 
pre- and postauthorization studies were disease registries, hospital 
data, claims/prescriptions/dispensing data, and electronic health 
care records.
Antineoplastic and immunomodulating agents accounted for 
over a third of initial MAAs and a half of EOIs submissions, and as 
such many applications where RWE was used. Many of these prod-
ucts are indicated for rare— often fatal diseases— with applications 
being based on uncontrolled clinical trials instead of traditional 
RCTs. In such cases, the use of RWE in submissions is to support 
demonstration of efficacy, for example, through provision of exter-
nal comparators in single arm studies. Depending on the role of 
the external comparator, the contribution could be designated as a 
“supportive” study or as part of the “main” study. Alternatively, the 
life- threatening nature of many cancers means that new treatments 
are often authorized under accelerated procedures and might be 
granted a conditional marketing authorization, pending additional 
evidence submitted postapproval. In this context, RWE can sup-
port postauthorization follow- up to confirm the long- term efficacy 
and safety needed for a full MAA, and in this context could be 
considered a “supportive” study. Work is ongoing to detail the type, 
purpose, and influence of RWD/RWE in the marketing authoriza-
tion process.
A predecessor to this study by Bouvy et al. found that for 392 
products that received a positive CHMP opinion from 2005– 
2013, there were 31 registries that were requested for 30 products 
(7.7%) in total (65% were product registries, 35% were disease 
registries) with 71% having a primary safety objective.15,16 This 
frequent use of product registries led to the establishment of the 
EMA Patient Registry initiative supporting the use of existing pa-
tient registries for the postauthorization benefit– risk monitoring 
of medicinal products.17 This was subsequently followed up with 
proposals for operational methods for increasing the use of patient 
registries in medicines regulation by addressing: the nature of the 
data collected and registry quality assurance processes; registry 
governance, informed consent, data protection, and sharing; and 
stakeholder communication and planning of benefit- risk assess-
ments.18 Although following a different methodology, we found 
an apparent increase in the extent of registry use compared to that 
found by Bouvy et al., with 24.1% of all MAA and 8.5% of all EOIs 
applications making use of registries. We found registries were used 
in 56.0% of cases where RWD was used: in 33.0% of applications 
these were disease registries, 13.2% product registries, and 16.5% 
other registries.
Previous studies have also highlighted the increasing impor-
tance of RWE to the regulatory decision- making process. A 
review of 52 referrals completed by the EMA between January 
2013 and June 2017, showed that noninterventional studies 
contributed to the evaluation of 59.6% of the referrals related 
to product safety and of 34.6% related to product efficacy.2 A 
further review of new drug applications identified 73 registries 
planned postauthorization, of which 39 aimed to collect safety 
outcomes and 7 aimed to collect safety outcomes and real- world 
effectiveness data.7 Using publicly available regulatory doc-
uments, a review of 415 EMA- approval decisions on pharma-
ceuticals from January 1, 1999, to May 8, 2014, found that 44 
indications for 35 products were approved on the basis of un-
controlled study data, including 8 extensions of indication for 
treatments with RCTs in other indications and 36 indications 
for products in which there were no RCT results in an approved 
indication.4 This study did not address the possible use of RWE 
as alternative supporting evidence. In the field of orphan medic-
inal products, a review of 125 dossiers published between 1999 
and 2014 found that 12% did not include evidence from clinical 
trials but were based on literature reports, observational studies, 
or compassionate use programs.19
The use of RWE in decision making for marketing authoriza-
tions depends on many factors, as summarized by Cave et al. in 
three categories: operational, technical, and methodological.1 
Essential factors to consider include: the information available in 
the data source, the quality and validity of this information, the de-
sign of the data collection, the statistical analytical plan supporting 
data analysis and interpretation, and the likelihood of bias due to 
the unblinded, uncontrolled, or nonrandomized treatment alloca-
tion.20 In some circumstances, scientific evaluation of the efficacy 
and safety of medicines prior to granting a marketing authoriza-
tion may be supported by observational evidence where an RCT 
is deemed not feasible or unethical. Prior consultation with the 
EMA via the procedure for scientific advice and protocol assistance 
is generally recommended to agree on the adequacy of a source of 
RWE to support marketing authorization.17
Our study has a number of strengths. First, we focused on 
MAAs and EOIs submitted over a 2- year period rather than those 
authorized, as performed by other recent studies.2,4,7 This allowed 
an exhaustive evaluation of the characteristics of RWE, including 
those in applications withdrawn during the evaluation procedure. 
Further research is needed to assess the impact of some of these 
characteristics on the acceptability of the authorization, and rea-
sons for decisions on withdrawal and refusal decisions. Second, the 
investigators had access to information available at the EMA and 
the original application files submitted by marketing authorization 
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applicants, some of which would not be available in the public do-
main. It allowed us to further validate or complement the informa-
tion available in published EPARs and RMPs. Third, to minimize 
heterogeneity in the way RWE was described and classified across 
applications, a quality control mechanism was put in place to take 
into account the fact that data extraction had to be performed by 
screening electronic documents with a distribution of the work-
load among seven investigators. This quality control mechanism 
did not identify significant systematic differences between inves-
tigators and contributed to consistent data extraction and catego-
rization. Finally, the exhaustive repository of RWE submitted to 
EMA over a 2- year period will allow further, more detailed eval-
uations of the usefulness and acceptability of RWE in application 
procedures.
The main limitation is the lack of internationally agreed guid-
ance for the operational definitions of RWD and RWE detailing 
which type of data should allow to identify an application con-
taining such features. The inclusion/exclusion criteria presented 
in Table 1 are the result of a consensus between the authors con-
sidering unforeseen types of data emerging during the period of 
data extraction and were guided by a shared view of RWD as 
those having high external validity and arising from routinely 
collected patient level data. This was informed by a definition 
of RWD excluding traditional clinical trials1— similar to one 
used previously by the FDA21— although we included trials that 
involved use of data collected from other sources, for example, 
single arm trials using such data as a comparator. However, we 
acknowledge that the terminology around this topic is nuanced: 
a more recent FDA definition of RWE includes evidence gener-
ated by different study designs or analyses, such as randomized 
and pragmatic trials.22 For the purposes of this study, we took 
the view that traditional RCTs and open- label follow- up of these 
RCTs do not constitute RWD/RWE, as the data generated in 
the open- label follow- up would not be independent from the ac-
tive phase of the RCT and therefore not necessarily represent a 
new research question addressed by RWD/RWE. We also con-
sidered the population of the original trial would typically not 
be representative of the underlying patient population. This is 
because trial design frequently lacks certain types of patients, a 
phenomenon partly mediated through the exclusion criteria in-
herent to the trial (for example, vulnerable patients, those with 
multiple comorbidities, or who are pregnant) and partly because 
trials routinely under- recruit certain categories of subjects, for 
example, ethnic minorities or those from socioeconomically dis-
advantaged backgrounds. Although we included patient surveys, 
other surveys, for example, healthcare professionals’ awareness of 
risk minimization measures, were excluded: the focus of much of 
the RWD was on patient- level data used to address drug safety 
or effectiveness outcomes, and this generally was not directly ad-
dressed by surveys of healthcare professionals.
Arguably, decisions around what was considered real- world 
were based on criteria defined by the investigators and other re-
search groups might have classified studies differently. Given that 
definitions of what constitutes RWD and RWE overlap with tra-
ditionally used dichotomous classification of clinical research as “in-
terventional vs. noninterventional,” “prospective vs. retrospective,” 
“externally valid vs. selected populations,” and “primary vs. second-
ary data collection,”8 there is undoubtedly a need for internation-
ally agreed criteria in this regard. A second limitation is that not all 
procedures had been finalized by August 12, 2020, which explains 
that, for 32.1% of products investigated, there was no information 
available on the final status of the application. The proportion of 
product with applications that are refused or withdrawn might 
change with time.
Future work will describe in further detail those studies that con-
tributed RWE to the regulatory application, for example, describ-
ing requests for, and outcome of, scientific advice, and focusing on 
how important RWD and RWE are to the regulatory evaluation 
and decision- making process. Such characteristics are more quali-
tative in nature and were beyond the scope of the current quanti-
tative study but will be analyzed in more detail in a second phase 
of this project. It is anticipated that this research will contribute 
to generating the evidence- base required to drive the EMA’s and 
other regulators’ use of RWE in decision making, ultimately ad-
vancing patient- centered access to medicines in partnership with 
healthcare systems.9
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